Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs Nuvalent Inc (NUVL) Price & Performance

Duolingo IncTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Nuvalent Inc — how do they compare? Duolingo Inc trades at $129.92 (market cap $5.98B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is the larger of the two by market cap, and Nuvalent Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.

DUOLNUVL
Market Cap
$5.98B$9.81B
Sector
TechnologyTechnology
52-Week High
$390.84$123.96
52-Week Low
$90.03$72.16
Enterprise Value
$4.82B$8.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

Duolingo (DUOL) trades at $132.34, up 6.08% in the last session, reflecting strong momentum. The stock shows bullish technical signals with support at $127 and resistance at $135. Fundamentally, revenue grew to $1.04 billion in 2025, with net income surging to $414 million, driven by robust user engagement and AI feature expansion. Recent earnings beats and a positive analyst consensus highlight investor confidence in the company's growth trajectory.

Outlook remains positive with AI-driven user growth and profitability, but risks include rising inference costs and competitive pressures. The stock offers growth potential, yet investors should monitor margin trends and market volatility. Analyst price targets suggest moderate upside from current levels, with a consensus of $108.29.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.

The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL